.jpg?format=webp&width=780)
The study aimed to assess the impact of obstructive sleep apnea (OSA) treatment on heart remodeling and diastolic dysfunction in patients with metabolic syndrome (MS). The study was conducted as a prespecified analysis of a randomized placebo‐controlled trial involving patients with MS and moderate-to-severe OSA, who underwent continuous positive airway pressure (CPAP) or nasal dilators (placebo) for 6 months. The study found that CPAP prevented atrial enlargement and increased the chance of diastolic dysfunction reversibility in patients with MS and OSA.
Like
Save
Share